Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009.
Metastatic colorectal cancer is a particularly frequent and severe cancer. Patients die mainly from metastatic disease; however, the survival of these patients has dramatically improved with the progress in chemotherapeutic regimens as new routes of administration and introduction of more potent cytotoxic agents administered in sequential 5-FU-folinic acid-irinotecan/5-FU-folinic acid-oxaliplatine strategies. Biologic therapies have been also developed targeting two different pathways, angiogenesis and the epidermal growth factor receptor. Their combination with chemotherapy leads to improved progression-free survival and overall survival in some cases as the addition of cetuximab in wild-type K-Ras tumors. The objectives of this expert conference were to review the different options, the available prognostic or predictive factors to optimally guide the treatment.
Adam
R
R
Centre Hépato-Biliaire, Assistance Publique-Hôpitaux de Paris Hôpital Paul Brousse, and University Paris-Sud, Unité Mixte de Recherche-S 776 and Institut National de la Santé et de la Recherche Médicale, Unité 776, Villejuif, France. Electronic address: rene.adam@pbr.aphp.fr.
Haller
D G
DG
Abramson Cancer Center, University of Pennsylvania, PA, USA.
Poston
G
G
Centre for Digestive Diseases, Aintree University Hospital, Liverpool, UK.
Raoul
J-L
JL
Department of Medical Oncology, Centre Eugene Marquis, Rennes.
Spano
J-P
JP
Service d'Oncologie Médicale, Groupe Hospitalier Pitie-salpetriere, Paris, France.
Tabernero
J
J
Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Van Cutsem
E
E
Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D006801:Humans; D009362:Neoplasm Metastasis; D016019:Survival Analysis
D000970:Antineoplastic Agents; D001688:Biological Products